What Biodextris does

Biodextris Inc. is a biologics contract development and manufacturing organization (CDMO) headquartered in Laval, Quebec, providing end-to-end services from preclinical development through clinical manufacturing for recombinant proteins, monoclonal antibodies, virus-like particles (VLPs), vaccines, and viral vectors. The company operates a 32,000 sq. ft. GMP-compliant facility with BSL2 cleanrooms, supporting microbial, mammalian, plant-based, and insect cell expression systems across 5–200L bioreactor scales, and produces material at scales from milligrams to tens of grams per batch. Biodextris's service portfolio is organized around four integrated pillars—analytical services, process development, GMP biomanufacturing, and QC testing—supported by advanced analytical instrumentation including Waters Xevo G3 QTof mass spectrometry for GMP multi-attribute method assays.

Revenue is generated through project-based CDMO contracts with biotech and pharmaceutical sponsors, priced on a custom quote basis per project scope, with multi-year engagement lengths spanning preclinical through clinical phases. The customer base spans innovative biotechs (Calder Biosciences, Aramis Biotechnologies), large pharmaceutical companies (a Top 20 global pharma client, Oragenics), and government/research entities (National Research Council Canada). The go-to-market is enterprise field sales supported by business development managers and, since June 2025, a CDMO veteran Executive Chairman and Chief Commercial Officer focused on global commercial expansion. A newly launched mRNA and plasmid biotherapeutics division extends the platform into next-generation modalities.

Founded in 2015 as a spin-off from GSK's biologics operations in Laval, Biodextris traces its lineage through Intellivax, ID Biomedical, and GSK. The company has been owned since 2021 by Archimed through Clean Biologics SAS, and the Laval facility was inaugurated in October 2024 following a nearly $25 million capital program—including $7.9 million in government grants from Investissement Québec and the federal CED—with planned headcount growth from 44 to 65 over the next three to five years.

Name

Biodextris

Legal name

Biodextris Inc.

Website

https://biodextris.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

11–50 employees

Short description

Biodextris is a Canadian biologics CDMO providing analytical services, process development, and GMP manufacturing of recombinant proteins, vaccines, and viral vectors for biotech and pharmaceutical sponsors from preclinical through clinical phases.

Ownership category

akta.pro rank

Product category

Biologics Contract Development and Manufacturing (CDMO)

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Process Development & Tech Transfer Services (upstream/downstream) (HLAAAKAF), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF), Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ), GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification) (HLAGAGAL)

Keywords

• Biologics CDMO
• GMP manufacturing services
• Vaccine contract manufacturing
• Process development services
• Analytical and QC testing

Headquarters

HQ city

Laval

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

1. Contract Development and Manufacturing Services: Biodextris generates revenue through long-term contract manufacturing agreements with biotech and pharmaceutical companies for the development, GMP manufacturing, and bioanalysis of biologics and vaccines. Revenue is project-based with engagement lengths spanning from preclinical through commercial phases.
2. Analytical and QC Testing Services: Fee-for-service analytical development, method validation, QC release testing, and stability studies for client products.
3. Process Development Services: Upstream and downstream process development, tech transfer, and process validation services for biologics and vaccine programs.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Biodextris is a biologics Contract Development and Manufacturing Organization (CDMO) providing end-to-end services from preclinical through clinical manufacturing for recombinant proteins, monoclonal antibodies, virus-like particles (VLPs), vaccines, viral vectors, and other complex biologics. The company's service portfolio spans four pillars: Analytical Services (method development, validation, transfer, and QC/stability testing), Process Development Services (upstream and downstream process development, tech transfer), GMP Biomanufacturing Services (production from milligrams to tens of grams per batch across microbial, mammalian, insect, and plant-based platforms), and Quality Control Testing. Services are delivered from a custom-designed 32,000 sq. ft. GMP facility in Laval, Quebec, featuring 6,500 sq. ft. of BSL2 cleanrooms, 5–200L bioreactors, and small-scale aseptic fill-finish for vials and prefilled syringes.

Product overview

Biodextris is a biologics CDMO (Contract Development and Manufacturing Organization) providing end-to-end services from preclinical to commercial manufacturing across four integrated service pillars: Analytical Services, Process Development Services, GMP Biomanufacturing Services, and general Quality Control Testing. These services are supported by specialized technology modules (physico-chemical/biophysical platforms, immunological/cell-based platforms, GMP mass spectrometry) and cover multiple production platforms (microbial, mammalian, insect cell, plant-based). The company produces recombinant proteins (antibodies, VLPs, antigens, enzymes) and non-recombinant biologics (viral vectors, plasmids, whole-cell vaccines). The portfolio is unified by the 5F CDMO operating model (Focused-on-Patients, Friendly, Flexible, Fast, Future-driven) and a shared GMP-compliant quality management system.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 17x higher neutralizing antibody response achieved for Calder Biosciences RSV vaccine compared to market-leading recombinant RSV vaccine
• +3 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Four partnerships are on record, tiered core.

• Aramis BiotechnologiescoreStrategic or Co-development Partner · 17 December 2024Strategic partnership for downstream manufacturing of Aramis' seasonal influenza VLP vaccine for Phase 1 & 2 clinical trials. Biodextris provides access to its state-of-the-art GMP facilities for timely production of high-quality clinical materials. Combines Aramis' plant-based production expertise with Biodextris' downstream manufacturing capabilities.
• Calder BiosciencescoreStrategic or Co-development Partner · 5 June 2023Clinical supply agreement for evaluation of DT-preF, Calder's lead RSV vaccine candidate, as part of Phase 1 clinical trial. Biodextris produces the vaccine using its novel manufacturing process. First contract for Biodextris' new GMP biomanufacturing facility.
• Clean Biologics SAScoreOthersParent company of Biodextris Inc. Clean Biologics provides clinical manufacturing process analysis, development services, and quality control testing as part of an integrated CDMO group serving vaccine and biologics industries.
• Clean Biologics GroupcoreStrategic or Co-development PartnerMulti-expertise CDMO organization that coordinates overall biopharma CDMO capacities across member companies including Biodextris, enabling integrated services for sponsors while maintaining segmented approach.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• AGC Biologics: Mid-to-large scale global biologics CDMO offering microbial and mammalian expression, viral vectors, and recombinant proteins from preclinical through commercial. Closely comparable to Biodextris in service mix but materially larger in scale.
• KBI Biologics: Specialist biologics CDMO providing mammalian and microbial process development, cGMP manufacturing, and analytical services for clinical-stage biotechs. Highly comparable in customer segment (clinical-stage biotechs) and service scope to Biodextris.
• Vibalogics: Specialist CDMO focused on viral vectors (AAV, lentivirus), vaccines, and oncolytic viruses for clinical and commercial supply. Directly comparable niche overlap with Biodextris's viral vector and vaccine manufacturing capabilities.
• Novasep: European-based CDMO offering process development and GMP manufacturing for biologics, viral vectors, and complex molecules. Directly comparable in scope to Biodextris's biologics process development and clinical manufacturing services.
• Emergent BioSolutions: Vaccines and biologics CDMO with BSL2/BSL3 capabilities, offering contract manufacturing services for vaccine and therapeutic biologics developers. Directly comparable niche overlap with Biodextris's BSL2 vaccine and biologics manufacturing focus.

Broad incumbents

• Lonza: World's largest biologics CDMO with mammalian and microbial expression, viral vectors, and mRNA capabilities across preclinical, clinical, and commercial scales. Represents the scale ceiling against which mid-sized CDMOs like Biodextris must differentiate.
• Catalent: Major global CDMO offering biologics development and manufacturing, fill-finish, and analytical services across modalities. Comparable to Biodextris in core biologics CDMO services but with substantially broader geographic and commercial reach.
• Fujifilm Diosynth Biotechnologies: Large-scale biologics CDMO offering microbial and mammalian expression, vaccine, and gene therapy manufacturing. Comparable service portfolio to Biodextris but operates at significantly larger scale with commercial manufacturing capacity.
• Thermofisher Scientific (Patheon): Global CDMO within Thermo Fisher offering biologics, sterile fill-finish, and analytical services through a broad pharma services platform. Provides scope and scale benchmark for the broader CDMO competitive set.

Emerging players

• Bionova Scientific: Mid-sized US biologics CDMO offering process development, analytical, and GMP manufacturing services for clinical-stage biotechs. Comparable customer focus and capability set to Biodextris, with a similar scale profile.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/biodextris

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biodextris